Relief of pain · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes participant‐reported pain relief compared with morphine (very low certainty).
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Hydromorphone showed no clear difference in average pain scores (0-100 VAS) compared with morphine; GRADE not reported.
1 finding from 1 review
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lack of efficacy withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain
1 finding from 1 review
Adverse event withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deaths · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
1 finding from 1 review